# A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01475292** · PHASE2 · COMPLETED · sponsor: **Respivert Ltd** · enrollment: 30 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** RV568
- **DRUG:** RV568
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01475292
- **Lead sponsor:** Respivert Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01475292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01475292, "A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01475292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*